Spire Wealth Management’s NovoCure NVCR Stock Holding History

Spire Wealth Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-20	Closed	-$830	–	2435
2023 Q2	$830	Hold	20	–	–	﹤0.01%	2330
2023 Q1	$1.2K	Sell	20 -13	-39%	-$1.04K	﹤0.01%	2367
2022 Q4	$2K	Buy	+33	New	+$2.48K	﹤0.01%	2076
2022 Q3	–	Sell	-100	Closed	-$7K	–	2473
2022 Q2	$7K	Hold	100	–	–	﹤0.01%	2037
2022 Q1	$8K	Sell	100 -27	-21%	-$1.99K	﹤0.01%	2114
2021 Q4	$10K	Buy	+127	New	+$12.7K	﹤0.01%	2388
2021 Q3	–	Sell	-187	Closed	-$41K	–	2626
2021 Q2	$41K	Buy	187 +3	+2%	+$584	﹤0.01%	1570
2021 Q1	$24K	Buy	+184	New	+$29.1K	﹤0.01%	2078

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Spire Wealth Management's NVCR Position: Q3 2023 in Review

Spire Wealth Management sold out of NovoCure (NVCR) in Q3 2023, closing a stake of 20 shares — an estimated $830 sold.

Spire Wealth Management first reported a position in NVCR in Q1 2021 and held it in 8 quarters. The position peaked at $41K in Q2 2021. 226 funds tracked by Wall St. Rank hold NVCR as of Q3 2023.

Spire Wealth Management reported no remaining NovoCure position as of Q3 2023 after selling out during the quarter.
Spire Wealth Management sold 20 NovoCure shares in Q3 2023, an estimated $830.
Spire Wealth Management first reported a position in NovoCure in Q1 2021 and held it in 8 quarters.
Spire Wealth Management's NovoCure position peaked at $41K in Q2 2021.
226 funds tracked by Wall St. Rank held NovoCure as of Q3 2023.

Based on Spire Wealth Management's 13F filing for Q3 2023, filed 8 Nov 2023.